1
|
Abstract
The phylogenetically ancient, pentraxin family of plasma proteins, comprises C-reactive protein (CRP) and serum amyloid P component (SAP) in humans and the homologous proteins in other species. They are composed of five, identical, non-covalently associated protomers arranged with cyclic pentameric symmetry in a disc-like configuration. Each protomer has a calcium dependent site that mediates the particular specific ligand binding responsible for all the rigorously established functional properties of these proteins. No genetic deficiency of either human CRP or SAP has been reported, nor even any sequence polymorphism in the proteins themselves. Although their actual functions in humans are therefore unknown, gene deletion studies in mice demonstrate that both proteins can contribute to innate immunity. CRP is the classical human acute phase protein, routinely measured in clinical practice worldwide to monitor disease activity. Human SAP, which is not an acute phase protein, is a universal constituent of all human amyloid deposits as a result of its avid specific binding to amyloid fibrils of all types. SAP thereby contributes to amyloid formation and persistence in vivo. Whole body radiolabelled SAP scintigraphy safely and non-invasively localizes and quantifies systemic amyloid deposits, and has transformed understanding of the natural history of amyloidosis and its response to treatment. Human SAP is also a therapeutic target, both in amyloidosis and Alzheimer's disease. Our drug, miridesap, depletes SAP from the blood and the brain and is currently being tested in the DESPIAD clinical trial in Alzheimer's disease. Meanwhile, the obligate therapeutic partnership of miridesap, to deplete circulating SAP, and dezamizumab, a humanized monoclonal anti-SAP antibody that targets residual SAP in amyloid deposits, produces unprecedented removal of amyloid from the tissues and improves organ function. Human CRP binds to dead and damaged cells in vivo and activates complement and this can exacerbate pre-existing tissue damage. The adverse effects of CRP are completely abrogated by compounds that block its binding to autologous ligands and we are developing CRP inhibitor drugs. The present personal and critical perspective on the pentraxins reports, for the first time, the key role of serendipity in our work since 1975. (345 words).
Collapse
Affiliation(s)
- Mark. B. Pepys
- Wolfson Drug Discovery Unit, Centre for Amyloidosis and Acute Phase Proteins, University College London, London, United Kingdom
- National Institute for Health Research University College London Hospitals Biomedical Research Centre, London, United Kingdom
| |
Collapse
|
2
|
Pepys MB, Gallimore JR, Lloyd J, Li Z, Graham D, Taylor GW, Ellmerich S, Mangione PP, Tennent GA, Hutchinson WL, Millar DJ, Bennett G, More J, Evans D, Mistry Y, Poole S, Hawkins PN. Isolation and characterization of pharmaceutical grade human pentraxins, serum amyloid P component and C-reactive protein, for clinical use. J Immunol Methods 2012; 384:92-102. [PMID: 22867744 PMCID: PMC4068106 DOI: 10.1016/j.jim.2012.07.013] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2012] [Revised: 07/19/2012] [Accepted: 07/23/2012] [Indexed: 12/11/2022]
Abstract
The human pentraxin proteins, serum amyloid P component
(SAP) and C‐reactive protein (CRP) are important in routine clinical diagnosis, SAP
for systemic amyloidosis and CRP for monitoring the non‐specific acute phase
response. They are also targets for novel therapies currently in development but
their roles in health and disease are controversial. Thus, both for clinical use and
to rigorously elucidate their functions, structurally and functionally intact,
pharmaceutical grade preparations of the natural, authentic proteins are required. We
report here the production from normal human donor plasma and the characterization of
the first such preparations. Importantly, we demonstrate that, contrary to reports
using recombinant proteins and less well characterized preparations, neither CRP nor
SAP stimulate the release by human peripheral blood mononuclear cells in
vitro of any TNFα, IL‐6 or IL‐8, nor does SAP cause release of IL‐1β
or IL‐10. Furthermore neither of our preparations was pro‐inflammatory in mice
in vivo.
Collapse
Affiliation(s)
- Mark B Pepys
- Wolfson Drug Discovery Unit, Centre for Amyloidosis and Acute Phase Proteins, Division of Medicine, University College London, Rowland Hill Street, London NW3 2PF, UK.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
3
|
Abstract
Scintigraphic imaging of radioiodinated serum amyloid P-component is a proven method for the clinical detection of peripheral amyloid deposits (Hawkins et al., 1990). However, the inability to perform comparably high-resolution studies in experimental animal models of amyloid disease has impacted not only basic studies into the pathogenesis of amyloidosis but also in the preclinical in vivo evaluation of potential anti-amyloid therapeutic agents. We have developed microimaging technologies, implemented novel computational methods, and established protocols to generate high-resolution images of amyloid deposits in mice. (125)I-labeled serum amyloid P component (SAP) and an amyloid-fibril reactive murine monoclonal antibody (designated 11-1F4) have been used successfully to acquire high-resolution single photon emission computed tomographic (SPECT) images that, when fused with x-ray computed tomographic (CT) data, have provided precise anatomical localization of secondary (AA) and primary (AL) amyloid deposits in mouse models of these diseases. This chapter will provide detailed protocols for the radioiodination and purification of amyloidophilic proteins and the generation of mouse models of AA and AL amyloidosis. A brief description of the available hardware and the parameters used to acquire high-resolution microSPECT and CT images is presented, and the tools used to perform image reconstruction and visualization that permit the analysis and presentation of image data are discussed. Finally, we provide established methods for measuring organ- and tissue-specific activities with which to corroborate the microSPECT and CT images.
Collapse
Affiliation(s)
- Jonathan S. Wall
- Human Immunology & Cancer Program, Department of Medicine, University of Tennessee Graduate School of Medicine, Knoxville, TN, USA ; Tel: (865) 544 9165; Fax: (865) 544 6865 ; Tel: (865) 544 9165; Fax: (865) 544 6865
| | - Michael J. Paulus
- Siemens Medical Solutions Molecular Imaging, LLC, 810 Innovation Drive, Knoxville, TN, USA ; Tel: (865) 218 1621 ; Tel: (865) 218 1642
| | - Shaun Gleason
- Siemens Medical Solutions Molecular Imaging, LLC, 810 Innovation Drive, Knoxville, TN, USA ; Tel: (865) 218 1621 ; Tel: (865) 218 1642
| | - Jens Gregor
- Department of Computer Science, University of Tennessee, 1122 Volunteer Blvd., Suite 203, Knoxville, TN 37996-3450 ; Tel: (865) 974 4399; Fax (865) 974 4404
| | - Alan Solomon
- Human Immunology & Cancer Program, Department of Medicine, University of Tennessee Graduate School of Medicine, Knoxville, TN, USA ; Tel: (865) 544 9165; Fax: (865) 544 6865 ; Tel: (865) 544 9165; Fax: (865) 544 6865
| | - Stephen J. Kennel
- Oak Ridge National Laboratory, Life Sciences Division, Bldg 4500S, Rm F150, Oak Ridge, TN ; Tel: (865) 574 0825; Fax: (865) 576-7651
| |
Collapse
|
4
|
|
5
|
Abstract
Demonstration of amyloid deposits in biopsy specimens is the only means of confirming the diagnosis of amyloidosis. In experienced hands, nonsurgical biopsies of the rectal mucosa or, preferably, of the abdominal fat pad or labial salivary glands provide the diagnosis in 80 to 85% of cases. Immunolabeling studies help to determine the histological type of amyloidosis but are not performed routinely in everyday practice. In patients with a family history of amyloidosis, studies of the genome and amyloid protein can identify the protein variants capable of causing systemic amyloidosis. Once the diagnosis of amyloidosis is established, the extent of systemic involvement with amyloid should be evaluated by performing renal and hepatic function tests, a proteinuria assay, and an echocardiogram. Scintigraphy with radiolabeled serum amyloid P (SAP) component is a rapid and specific investigation that provides a map of the amyloid deposits. Deposits are usually seen in the liver and spleen. SAP component scintigraphy can provide support for the diagnosis of amyloidosis in patients with negative histological studies. Tissue retention of radioactivity predicts survival.
Collapse
Affiliation(s)
- Eric Hachulla
- Internal medicine department, Centre hospitalier régional et universitaire, Hôpital Claude Huriez, 59037, Lille cedex, France.
| | | |
Collapse
|
6
|
Abstract
INTRODUCTION Recent data in amyloid research have shed light on the amyloid substance and have broadened our knowledge on the mechanism of amyloid deposition. CURRENT KNOWLEDGE AND KEY POINTS Despite uniform physical properties relating to the presence of beta-pleates, amyloid deposits are chemically heterogeneous and have different origins; additional types will probably be described in the future. Immunohistochemical techniques using specific antisera for each of the major protein present in fibrils could help greatly to subclassify these disorders. In most circumstances, a circulating precursor protein may result from overproduction of either intact or aberrant molecule, a reduction in its degradation or excretion, or genetic abnormalities associated with variant proteins. The cleavage of protein precursor molecules of the protein component of amyloid fibrils characterizes amyloidogenesis, though it is not necessary for some amyloidosis forms. This review summarizes advances in the understanding of the nature of amyloid substances, the mechanism of amyloid deposition and the principal pathogenic hypothesis. FUTURE PROSPECTS AND PROJECTS SAP component is common in all amyloidosis and may be the target for future therapy.
Collapse
Affiliation(s)
- H Lebrazi
- Laboratoire de biochimie, faculté des sciences Ben M'sik, Casablanca, Maroc
| | | | | |
Collapse
|
7
|
Botto M, Hawkins PN, Bickerstaff MC, Herbert J, Bygrave AE, McBride A, Hutchinson WL, Tennent GA, Walport MJ, Pepys MB. Amyloid deposition is delayed in mice with targeted deletion of the serum amyloid P component gene. Nat Med 1997; 3:855-9. [PMID: 9256275 DOI: 10.1038/nm0897-855] [Citation(s) in RCA: 177] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
The tissue amyloid deposits that characterize systemic amyloidosis, Alzheimer's disease and the transmissible spongiform encephalopathies always contain serum amyloid P component (SAP) bound to the amyloid fibrils. We have previously proposed that this normal plasma protein may contribute to amyloidogenesis by stabilizing the deposits. Here we show that the induction of reactive amyloidosis is retarded in mice with targeted deletion of the SAP gene. This first demonstration of the participation of SAP in pathogenesis of amyloidosis in vivo confirms that inhibition of SAP binding to amyloid fibrils is an attractive therapeutic target in a range of serious human diseases.
Collapse
Affiliation(s)
- M Botto
- Rheumatology Unit, Royal Postgraduate Medical School, Hammersmith Hospital, London, UK
| | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Hawkins PN, Pepys MB. Imaging amyloidosis with radiolabelled SAP. EUROPEAN JOURNAL OF NUCLEAR MEDICINE 1995; 22:595-9. [PMID: 7498219 DOI: 10.1007/bf01254559] [Citation(s) in RCA: 66] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
|
9
|
Piirsalu K, McLean R, Zuber R, Bannistert K, Penglis S, Bellen J, Bais R. Role of 1–123 serum amyloid Srotein in the etection of familial amyloidosis in Oriental cats. J Small Anim Pract 1994. [DOI: 10.1111/j.1748-5827.1994.tb03824.x] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
10
|
Hawkins PN, Wootton R, Pepys MB. Metabolic studies of radioiodinated serum amyloid P component in normal subjects and patients with systemic amyloidosis. J Clin Invest 1990; 86:1862-9. [PMID: 2254450 PMCID: PMC329819 DOI: 10.1172/jci114917] [Citation(s) in RCA: 70] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
125I-Serum amyloid P component (SAP), injected intravenously into 10 normal subjects, remained predominantly intravascular with mean (SD) T1/2 (half time) in plasma of 24.5 (5.9) h. The fractional catabolic rate of 68 (19)% of the plasma pool per day was more rapid than other reported human plasma proteins. All radioactivity was excreted in the urine by 14 d. In 16 patients with monoclonal gammopathy or chronic inflammatory diseases, but without amyloidosis, 125I-SAP metabolism was normal. However, among 45 patients with biopsy-proven systemic amyloidosis (25, amyloid A type; 20, amyloid L type), 125I-SAP was cleared from the plasma more rapidly, accumulated in the amyloid deposits, and persisted there. The T1/2 in amyloid, measured directly with 131I-SAP, was 24 d. Repeat studies after 6-18 mo were notably consistent in normals but changed significantly in amyloid patients, generally correlating with clinical signs of disease progression. Measurements of 125I-SAP turnover may thus be of value for diagnosis and monitoring of amyloidosis. Analysis of SAP metabolism in amyloidosis suggests that plasma SAP is in dynamic equilibrium with a very large amyloid pool, and in two autopsies the total mass of SAP in the amyloid deposits was 2,100 and 21,000 mg, respectively.
Collapse
Affiliation(s)
- P N Hawkins
- Department of Medicine, Royal Postgraduate Medical School, Hammersmith Hospital, London, United Kingdom
| | | | | |
Collapse
|
11
|
Hawkins PN, Lavender JP, Pepys MB. Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component. N Engl J Med 1990; 323:508-13. [PMID: 2377176 DOI: 10.1056/nejm199008233230803] [Citation(s) in RCA: 338] [Impact Index Per Article: 9.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
BACKGROUND In systemic amyloidosis the distribution and progression of disease have been difficult to monitor, because they can be demonstrated only by biopsy. Serum amyloid P component (SAP) is a normal circulating plasma protein that is deposited on amyloid fibrils because of its specific binding affinity for them. We investigated whether labeled SAP could be used to locate amyloid deposits. METHODS Purified human SAP labeled with iodine-123 was given intravenously to 50 patients with biopsy-proved systemic amyloidosis--25 with the AL (primary) type and 25 with the AA (secondary) type--and to 26 control patients with disease and 10 healthy subjects. Whole-body images and regional views were obtained after 24 hours and read in a blinded fashion. RESULTS In the patients with amyloidosis the 123I-SAP was localized rapidly and specifically in amyloid deposits. The scintigraphic images obtained were characteristic and appeared to identify the extent of amyloid deposition in all 50 patients. There was no uptake of the 123I-SAP by the control patients and the healthy subjects. In all patients with AA amyloidosis the spleen was affected, whereas the scans showed uptake in the heart, skin, carpal region, and bone marrow only in patients with the AL type. Positive images were seen in six patients in whom biopsies had been negative or unsuccessful; in all six, amyloid was subsequently found on biopsy or at autopsy. Progressive amyloid deposition was observed in 9 of 11 patients studied serially. CONCLUSIONS Scintigraphy after the injection of 123I-SAP can be used for diagnosing, locating, and monitoring the extent of systemic amyloidosis.
Collapse
Affiliation(s)
- P N Hawkins
- Department of Medicine, Royal Postgraduate Medical School, Hammersmith Hospital, London, United Kingdom
| | | | | |
Collapse
|
12
|
Hawkins PN, Pepys MB. A primed state exists in vivo following histological regression of amyloidosis. Clin Exp Immunol 1990; 81:325-8. [PMID: 2387095 PMCID: PMC1535055 DOI: 10.1111/j.1365-2249.1990.tb03339.x] [Citation(s) in RCA: 29] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
Using a sensitive, quantitative, and non-invasive in vivo method, based on the specific binding of serum amyloid P component to amyloid fibrils, we have directly documented the spontaneous resolution of AA amyloid deposits in mice, and the prolonged existence thereafter of a primed state of enhanced susceptibility to further amyloid deposition. These results may have important implications for understanding and management of amyloidosis in humans.
Collapse
Affiliation(s)
- P N Hawkins
- Department of Medicine, Royal Postgraduate Medical School, London, England, UK
| | | |
Collapse
|
13
|
Affiliation(s)
- R A Kyle
- Mayo Medical School, Rochester, Minnesota
| | | |
Collapse
|
14
|
|
15
|
Abstract
The clinical amyloidosis syndromes are a heterogeneous group of disorders characterised by abnormal extracellular accumulation of autologous protein material. Amyloid deposits are largely composed of insoluble protein fibrils which are intimately associated with sulphated glycosaminoglycan residues. Amyloid P component (AP) is a minor but almost universal constituent of the deposits and is derived from the normal circulating glycoprotein serum amyloid P component (SAP), a member of the pentraxin family of plasma proteins. The current classification of amyloidosis is based on the chemical nature of the fibril protein subunits. Systemic amyloidosis is well known as a relatively rare but important cause of serious morbidity, and vital organ involvement is usually fatal. In recent years it has become increasingly recognised that amyloid deposition in a variety of sites is a universal feature of ageing, and in particular that amyloid in the cerebral blood vessels and within the brain itself is an integral part of the pathology of Alzheimer's disease. Also recently, a new form of amyloid has emerged, confined to patients who have received long term haemodialysis for end stage renal failure, in whom beta 2-microglobulin (beta 2M) is laid down as amyloid fibrils predominantly in periarticular and bony tissues. Considerable progress in knowledge of the composition, molecular structure and properties of many different constituents of amyloid has been made in the past 30 years. However, the precise mechanisms of amyloid fibril formation, deposition and persistence are not known and no generally effective therapy yet exists which can arrest amyloid deposition or promote its resolution. A major reason for our ignorance of the natural history of amyloidosis is that it is an exclusively histological diagnosis, at the time of which most patients with systemic disease have extensive amyloid deposits throughout many organs and a very poor prognosis. Some optimism has been generated from recent work suggesting that amyloid fibrils are not inherently non-biodegradable and that the use of radiolabelled SAP may permit non-invasive sensitive, scintigraphic imaging of amyloid deposits in vivo.
Collapse
Affiliation(s)
- P N Hawkins
- Department of Medicine, Royal Postgraduate Medical School, London, UK
| |
Collapse
|
16
|
Hawkins PN, Myers MJ, Lavender JP, Pepys MB. Diagnostic radionuclide imaging of amyloid: biological targeting by circulating human serum amyloid P component. Lancet 1988; 1:1413-8. [PMID: 2898580 DOI: 10.1016/s0140-6736(88)92235-0] [Citation(s) in RCA: 150] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
The specific molecular affinity of the normal plasma protein, serum amyloid P component (SAP), for all known types of amyloid fibrils was used to develop a new general diagnostic method for in-vivo radionuclide imaging of amyloid deposits. After intravenous injection of 123I-labelled purified human SAP there was specific uptake into amyloid deposits in all affected patients, 7 with systemic AL amyloid, 5 with AA amyloid, and 2 with beta 2M amyloid, in contrast to the complete absence of any tissue localisation in 5 control subjects. Distinctive high-resolution scintigraphic images, even of minor deposits in the carpal regions, bone marrow, or adrenals, were obtained. This procedure should yield much information on the natural history and the management of amyloidosis, the presence of which has hitherto been confirmed only by biopsy. Clearance and metabolic studies indicated that, in the presence of extensive amyloidosis, the rate of synthesis of SAP was greatly increased despite maintenance of normal plasma levels. Furthermore, once localised to amyloid deposits the 123I-SAP persisted for long periods and was apparently protected from its normal rapid degradation. These findings shed new light on the pathophysiology of amyloid and may have implications for therapeutic strategies based upon specific molecular targeting with SAP.
Collapse
Affiliation(s)
- P N Hawkins
- Department of Medicine, Royal Postgraduate Medical School, Hammersmith Hospital, London
| | | | | | | |
Collapse
|
17
|
Hawkins PN, Myers MJ, Epenetos AA, Caspi D, Pepys MB. Specific localization and imaging of amyloid deposits in vivo using 123I-labeled serum amyloid P component. J Exp Med 1988; 167:903-13. [PMID: 3351437 PMCID: PMC2188867 DOI: 10.1084/jem.167.3.903] [Citation(s) in RCA: 71] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023] Open
Abstract
Highly specific, high-resolution scintigraphic images of amyloid-laden organs in mice with experimentally induced amyloid A protein (AA) amyloidosis were obtained after intravenous injection of 123I-labeled serum amyloid P component (SAP). Interestingly, a much higher proportion (up to 40%) of the injected dose of heterologous human SAP localized to amyloid and was retained there than was the case with isologous mouse SAP, indicating that human SAP binds more avidly to mouse AA fibrils than does mouse SAP. Specificity of SAP localization was established by the failure of the related proteins, human C-reactive protein and Limulus C-reactive protein, to deposit significantly in amyloid and by the absence of human SAP deposition in nonamyloidotic organs. However, only partial correlations were observed between the quantity of SAP localized and two independent estimates, histology and RIA for AA of the amount of amyloid in particular organs. It is not clear which of the three methods used reflects better the extent or clinical significance of the amyloid deposits but in vivo localization of radiolabeled SAP, detectable and quantifiable by gamma camera imaging, is apparently extremely sensitive. These findings establish the use of labeled SAP as a noninvasive in vivo diagnostic probe in experimental amyloidosis, potentially capable of revealing the natural history of the condition, and suggest that it may also be applicable generally as a specific targeting agent for diagnostic and even therapeutic purposes in clinical amyloidosis.
Collapse
Affiliation(s)
- P N Hawkins
- Department of Medicine, Royal Postgraduate Medical School, Hammersmith Hospital, London, England
| | | | | | | | | |
Collapse
|